Similar to the MM.1S cell line, CXCR4 co-expression endowed CAR NK-92 cells with much stronger cytolytic capacity against primary MM cells (Supplementary Figure S4C) at low effector to target ratios (E:T: 0.25:1), which even exceeded the gain-of-function compared to RajiBCMA and MM.1S cells (Figures 3C, D). This evidence concerns the gene CXCR4 and Miyoshi myopathy.